AzTrials
AzTrials

Upper Tract Urothelial CarcinomaUTLUNDNCT07321210

Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC)

A study testing Template Lymph Node Dissection and Selective Lymph Node Resection in people with Upper Tract Urothelial Carcinoma and Lymph Node Dissection, run by Tianjin Medical University Second Hospital at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn if adding a template lymph node dissection (TLND) to the standard surgery for upper tract urothelial cancer (UTUC) can improve patient survival and prevent the cancer from recurrence. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Template Lymph Node Dissection and Selective Lymph Node Resection
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
150 participants
Where
1 siteChina
Study dates
1 Sep 2025to 30 Aug 2032
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Signed written informed consent form (ICF).
  • Age > 18 years at the time of ICF signing.
  • Clinical diagnosis of unilateral Upper Tract Urothelial Carcinoma (UTUC) by imaging (enhanced CT or MRI) and/or ureteroscopic biopsy/urinary cytology, and scheduled to undergo Radical Nephroureterectomy (RNU).
  • Clinical assessment indicating that the tumor and regional lymph nodes are completely resectable, with at least one of the following high-risk features:
  • Locally advanced: Preoperative imaging assessed as cT2 stage or higher (i.e., tumor invades muscularis propria or deeper).
  • High-grade: Preoperative ureteroscopic biopsy pathology confirmed as high-grade urothelial carcinoma (or with squamous differentiation/sarcomatoid differentiation).
Show all 17Show fewer
  • Moderate or severe hydronephrosis: Ipsilateral moderate or severe hydronephrosis due to tumor obstruction.
  • Large tumor size: Imaging measures maximum tumor diameter > 2 cm.
  • cN1: Imaging suggests regional lymph node short-axis diameter > 1 cm, and the investigator judges it to be resectable.
  • Presence of at least one measurable lesion according to RECIST v1.1 criteria.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate organ function meeting the following requirements (without use of any blood components or colony-stimulating factors within 14 days):
  • Bone marrow function: Neutrophils ≥ 1,500/mm³, Platelets ≥ 100,000/mm³, Hemoglobin ≥ 9 g/dL (5.6 mmol/L).
  • Renal function: Serum creatinine ≤ 1.5 mg/dL and/or Creatinine clearance ≥ 60 mL/min.
  • Liver function: Total bilirubin ≤ 1.5 × ULN, AST \& ALT ≤ 1.5 × ULN.
  • For women of childbearing potential (WOCBP): Must agree to use a highly effective medically approved contraceptive method during the treatment period and for 3 months after treatment ends. A negative serum or urine pregnancy test within 7 days before enrollment is required; must be non-lactating. For non-sterilized male patients: Must agree to use effective contraception with their partner during the treatment period and for 3 months after treatment ends.
  • Subject voluntarily joins the study, has good compliance, and agrees to undergo safety and survival follow-up.

Who cannot join

  • Previous receipt of any anti-tumor therapy for UTUC, including chemotherapy, radiotherapy, immunotherapy, or targeted therapy.
  • History or concurrent presence of muscle-invasive bladder urothelial carcinoma.
  • Preoperative imaging assesses regional lymph nodes as unresectable: lymph nodes fused into a massive conglomerate, or fully encasing the abdominal aorta/inferior vena cava/pelvic vessels preventing safe separation.
  • Known bilateral UTUC or hereditary diseases that definitively increase the risk of contralateral upper tract tumors, such as Lynch Syndrome.
  • Diagnosis of other active malignancies within the past 5 years (except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix which have been cured and show no recurrence within 5 years).
  • Presence of any active autoimmune disease or history of autoimmune disease.
Show all 19Show fewer
  • Current use of immunosuppressants for immunosuppressive purposes, continued within 2 weeks prior to enrollment.
  • Poorly controlled cardiac clinical symptoms or diseases.
  • Coagulation abnormalities or bleeding tendency.
  • Presence of specific active gastrointestinal conditions or uncontrolled tumor bleeding.
  • History of significant bleeding, hemoptysis, or thromboembolic events within specified timeframes.
  • Active infection or unexplained fever > 38.5°C during screening or before the first dose.
  • Occurrence of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to surgery.
  • History or current objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severely impaired pulmonary function, etc.
  • Congenital or acquired immunodeficiency.
  • Participation in another clinical study within 1 month prior to enrollment, or potential receipt of other systemic anti-tumor therapy during the study period.
  • Known history of psychotropic drug abuse, alcohol abuse, or drug use.
  • Inability or unwillingness to bear the out-of-pocket costs of examinations and treatments.
  • Any other condition deemed by the investigator to make the subject unsuitable for participation.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Shimiao Zhu, MD, PhD contact

+86 88328607

zhushimiao@tmu.edu.cn

China1 site, 1 recruiting

  • Tianjin Medical University Second Hospital

    Tianjin, Tianjin Municipality, 300211

    Changyi Quan, MD, 13388067990, 345920147@qq.com

    Shimiao Zhu, PhD, MD

    Recruiting

Other trials in China

About this study

Official title: Clinical Efficacy and Safety of Radical Nephroureterectomy With Versus Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma: A Multicenter, Prospective, Randomized Controlled Clinical Trial

The goal of this clinical trial is to learn if adding a template lymph node dissection (TLND) to the standard surgery for upper tract urothelial cancer (UTUC) can improve patient survival and prevent the cancer from recurrence. The main questions it aims to answer are:

Do patients who receive standard surgery with LND live longer without their cancer returning? Is adding LND safe, and how does it affect surgery-related complications? Researchers will compare the group receiving standard surgery plus LND to the group receiving standard surgery alone to see if adding LND is more effective.

Read more

Participants will:

Be randomly assigned to one of the two surgical groups. Undergo their assigned surgery and recover in the hospital. Attend regular follow-up visits for checkups and scans for 5 years to monitor for cancer recurrence, with the possibility of long-term follow-up extending to 10 years.

Read the detailed description

Background： Upper tract urothelial carcinoma (UTUC), encompassing renal pelvic and ureteral carcinomas, is a relatively rare but aggressive malignancy of the urinary system, accounting for 5-10% of all urothelial cancers. Radical nephroureterectomy (RNU) with bladder cuff excision remains the gold standard for treating non-metastatic UTUC. However, prognosis remains poor, particularly for patients with locally advanced disease, due to high rates of recurrence and metastasis. The role of concurrent lymph node dissection (LND) during RNU is one of the most debated topics in UTUC management. While LND is widely accepted in muscle-invasive bladder cancer for its diagnostic and therapeutic benefits, its utility in UTUC lacks high-level evidence. Current guidelines conditionally recommend LND for high-risk UTUC based largely on retrospective data, leading to significant heterogeneity in clinical practice. This multicenter, prospective, randomized controlled trial aims to definitively establish the clinical value of template-based LND in high-risk UTUC.

Objectives：

  1. Primary Objectives:
  2. To compare the impact of RNU plus template LND versus RNU alone on disease-free survival (DFS) and overall survival (OS) in patients with high-risk non-metastatic UTUC.
  3. To evaluate and compare the safety profiles of both approaches, including perioperative complications (graded by Clavien-Dindo), operative time, intraoperative blood loss, and length of hospital stay.
  4. Secondary Objectives:
  5. To compare non-urothelial tract recurrence-free survival (NU-RFS), intravesical recurrence-free survival (IFS), and cancer-specific survival (CSS) between the two groups.
  6. To establish a lymph node metastasis (pN+) mapping profile for different UTUC tumor locations using template-based LND.
  7. Exploratory Objectives:
  8. To identify molecular biomarkers predictive of prognosis using bulk RNA sequencing of prospectively collected tumor tissues.
  9. To develop a lymph node metastasis prediction nomogram based on radiomic data from contrast-enhanced CT, tumor characteristics, lymph node size/location, and clinical symptoms.

Methods：

This is a prospective, multicenter, open-label, randomized controlled trial. A total of 150 eligible patients with high-risk UTUC (cT2-4N0-1M0 or cT1N1M0) will be randomized in a 1:1 ratio to one of two arms:

Experimental Arm (A): RNU + template LND Control Arm (B): RNU + removal of only radiologically or intraoperatively detected lymph nodes >1 cm Stratified randomization will be performed based on tumor location (renal pelvis/upper ureter, mid-ureter, lower ureter) and clinical nodal status (cN0 vs. cN1). Surgical approach (open, laparoscopic, or robotic) will be at the surgeon's discretion, but LND must adhere to predefined anatomical templates.

Patients will be followed for up to 10 years, with regular imaging, urine cytology, and cystoscopy according to a standardized schedule. DFS, OS, and other survival endpoints will be analyzed using Kaplan-Meier methods and Cox proportional hazards models. Safety will be assessed via Clavien-Dindo grading and monitoring of adverse events.

Innovation：

This trial addresses a critical evidence gap in UTUC management by providing the first high-level, prospective, randomized data on the therapeutic efficacy of template LND. Key innovative aspects include:

  1. Standardization of LND templates based on tumor location, enhancing surgical consistency and pathological staging.
  2. Incorporation of biomarker and radiomic analyses to explore predictive signatures for lymph node involvement and survival.
  3. A multicenter design ensuring generalizability and sufficient power to detect clinically meaningful differences in survival outcomes.
  4. Potential to establish LND as a standard of care for high-risk UTUC, thereby informing future guidelines and improving oncologic outcomes.
Being tested
Template Lymph Node Dissection, Selective Lymph Node Resection
Keywords
Upper tract urothelial carcinoma (UTUC), Template Lymph node dissection, Nephroureterectomy, High-risk neoplasm, Randomized Controlled Trial

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Template Lymph Node DissectionProcedure or surgery

    A systematic and anatomic-based lymph node dissection performed during radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). The dissection boundaries are strictly defined by a pre-specified template according to the primary tumor location: renal hilum+para-aortic (left hilar and paraaortic) or renal hilum+para-caval (right hilar, paracaval, and interaortocaval) for renal pelvis/upper ureter; extended to common/external iliac for mid-ureter; and pelvic (common, external, internal iliac, and obturator) for lower ureter. The goal is potential therapeutic benefit by removing nodal metastatic disease.

  • Selective Lymph Node ResectionProcedure or surgery

    A diagnostic procedure performed during radical nephroureterectomy (RNU). It does not involve a systematic template dissection. The surgeon will only remove intraoperatively identified suspicious and radiographic lymphadenopathy (>1 cm in the short-axis diameter). The primary goal is pathological staging rather than therapeutic clearance of a nodal basin.

Study groups in NCT07321210
Study groupRoleWhat they receive
RNU + Template Lymph Node DissectionExperimentalParticipants in this arm will undergo Radical Nephroureterectomy (RNU) combined with template Lymph Node Dissection (LND). The LND will be performed according to a predefined template based on the primary tumor location: renal hilum+para-aortic (left hilar and paraaortic) or renal hilum+para-caval (right hilar, paracaval, and interaortocaval) for renal pelvis/upper ureter; extended to common/external iliac for mid-ureter; and pelvic (common, external, internal iliac, and obturator) for lower ureter. The surgical approach (open, laparoscopic, or robot-assisted) is at the surgeon's discretion.
Receives: Procedure: Template Lymph Node Dissection
RNU + Selective Lymph Node ResectionActive comparatorParticipants in this arm will undergo Radical Nephroureterectomy (RNU) alone. No template lymph node dissection will be performed. However, if intraoperatively identified suspicious and radiographic lymphadenopathy (>1 cm in the short-axis diameter) are present, they may be removed for pathological staging purposes only.
Receives: Procedure: Selective Lymph Node Resection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Disease-Free Survival (DFS)

    Time from randomization to the first documented occurrence of disease recurrence (local, regional nodal, or distant metastasis), new urothelial carcinoma in the contralateral upper tract or bladder, or death from any cause, whichever occurs first.

    Measured: From date of randomization until the date of first documented progression, recurrence, or death from any cause, assessed up to 5 years. (Assessments: every 3 months for the first 2 years, then every 6 months for years 3-5.)

  2. Overall Survival (OS)

    Time from randomization to death from any cause.

    Measured: From date of randomization until the date of death from any cause, assessed up to 5 years. (Assessments: every 3 months.)

  3. Incidence and Severity of Postoperative Complications (Perioperative Safety)

    A composite measure to assess the safety of the surgical procedures, including:

    Incidence and severity of postoperative complications graded by Clavien-Dindo classification.

    Operative time (minutes). Estimated intraoperative blood loss (milliliters). Length of postoperative hospital stay (days).

    Measured: From the date of surgery until 30 days post-operation.

Secondary outcomes (4)

  1. Non-Urothelial Tract Recurrence-Free Survival (NU-RFS)

    Time from randomization to the first documented recurrence at a local site, regional lymph nodes, distant metastasis, or death from any cause, whichever occurs first.

    Measured: From date of randomization until the date of first documented non-urothelial recurrence or death, assessed up to 5 years. (Assessments: every 3 months for the first 2 years, then every 6 months for years 3-5.)

  2. Intravesical Recurrence-Free Survival (IFS)

    Time from randomization to the first documented occurrence of new urothelial carcinoma in the bladder or contralateral upper tract, or death from any cause, whichever occurs first.

    Measured: From date of randomization until the date of first documented intravesical recurrence or death, assessed up to 5 years. (Assessments: cystoscopy every 6 months for the first 2 years, then as per protocol.)

  3. Cancer-Specific Survival (CSS)

    Time from randomization to death attributable to urothelial carcinoma.

    Measured: Time Frame: From date of randomization until the date of death due to urothelial carcinoma, assessed up to 5 years. (Assessments: every 3 months.)

  4. Lymph Node Metastasis Map

    The distribution and positive rate (pN+%) of lymph node metastases, mapped according to the predefined template dissection locations for different primary tumor sites (renal pelvis/upper ureter, mid-ureter, lower ureter).

    Measured: At time of surgery (from final pathological report, approximately 4 weeks post-operation)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jan 2026
  2. Study start1 Sep 2025
  3. Primary completion30 Aug 2027 (estimated)
  4. Study completion30 Aug 2032 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07321210
Sponsor's protocol ID
TLND-UTUC
Acronym
UTLUND
Status last verified
Jun 2026
First submitted
21 Dec 2025
Last updated
25 Jun 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Hsieh HC, Wang CL, Chen CS, Yang CK, Li JR, Wang SS, Cheng CL, Lin CY, Chiu KY. The prognostic impact of lymph node dissection for clinically node-negative upper urinary tract urothelial carcinoma in patients who are treated with radical nephroureterectomy. PLoS One. 2022 Dec 1;17(12):e0278038. doi: 10.1371/journal.pone.0278038. eCollection 2022.

    PubMed 36454803

  • Bobjer J, Gerdtsson A, Abrahamsson J, Baseckas G, Bergkvist M, Blackberg M, Brandstedt J, Jancke G, Hagberg O, Kollberg P, Lundstrom KJ, Lofgren A, Nyberg M, Rian Martensson L, Saemundsson Y, Stahl E, Sorenby A, Warnolf A, Liedberg F. Location of Retroperitoneal Lymph Node Metastases in Upper Tract Urothelial Carcinoma: Results from a Prospective Lymph Node Mapping Study. Eur Urol Open Sci. 2023 Sep 27;57:37-44. doi: 10.1016/j.euros.2023.09.010. eCollection 2023 Nov.

    PubMed 38020529

  • Li X, Cui M, Gu X, Fang D, Li H, Qin S, Yang K, Zhu T, Li X, Zhou L, Gao XS, Wang D. Pattern and risk factors of local recurrence after nephroureterectomy for upper tract urothelial carcinoma. World J Surg Oncol. 2020 May 30;18(1):114. doi: 10.1186/s12957-020-01877-w.

    PubMed 32473636

  • Zareba P, Rosenzweig B, Winer AG, Coleman JA. Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract. Cancer. 2017 May 15;123(10):1741-1750. doi: 10.1002/cncr.30516. Epub 2017 Feb 2.

    PubMed 28152158

  • Huang J, Qian H, Yuan Y, Cai X, Chen Y, Zhang J, Kong W, Wu X, Cao M, Huang Y, Chen H, Xue W. Prospective Clinical Trial of the Oncologic Outcomes and Safety of Extraperitoneal Laparoscopic Extended Retroperitoneal Lymph Node Dissection at Time of Nephroureterectomy for Upper Tract Urothelial Carcinoma. Front Oncol. 2022 Feb 24;12:791140. doi: 10.3389/fonc.2022.791140. eCollection 2022.

    PubMed 35280720

  • Zhai TS, Jin L, Zhou Z, Liu X, Liu H, Chen W, Lu JY, Yao XD, Feng LM, Ye L. Effect of lymph node dissection on stage-specific survival in patients with upper urinary tract urothelial carcinoma treated with nephroureterectomy. BMC Cancer. 2019 Dec 12;19(1):1207. doi: 10.1186/s12885-019-6364-z.

    PubMed 31830927

  • Messer J, Lin YK, Raman JD. The role of lymphadenectomy for upper tract urothelial carcinoma. Nat Rev Urol. 2011 May 24;8(7):394-401. doi: 10.1038/nrurol.2011.78.

    PubMed 21606972

  • Roscigno M, Brausi M, Heidenreich A, Lotan Y, Margulis V, Shariat SF, Van Poppel H, Zigeuner R. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol. 2011 Oct;60(4):776-83. doi: 10.1016/j.eururo.2011.07.009. Epub 2011 Jul 14.

    PubMed 21798659

  • Raza SJ, Miller C, May A, Davaro F, Siddiqui SA, Hamilton Z. Lymph node density for stratification of survival outcomes with node positive upper tract urothelial carcinoma. Can J Urol. 2019 Aug;26(4):9852-9858.

    PubMed 31469641

  • Sato R, Watanabe K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Prognostic assessments in patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy and systematic regional lymph node dissection. Urologia. 2022 Aug;89(3):354-357. doi: 10.1177/03915603211034943. Epub 2021 Jul 29.

    PubMed 34325582

  • Piontkowski AJ, Corsi N, Morisetty S, Majdalany S, Rakic I, Li P, Arora S, Jamil M, Rogers C, Autorino R, Abdollah F. Benefit of lymph node dissection in cN+ patients in the treatment of upper tract urothelial carcinoma: Analysis of NCDB registry. Urol Oncol. 2022 Sep;40(9):409.e9-409.e17. doi: 10.1016/j.urolonc.2022.04.015. Epub 2022 May 24.

    PubMed 35623996

  • Fajkovic H, Cha EK, Jeldres C, Donner G, Chromecki TF, Margulis V, Novara G, Lotan Y, Raman JD, Kassouf W, Seitz C, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Breinl E, Pycha A, Ficarra V, Montorsi F, Karakiewicz PI, Scherr DS, Shariat SF. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. J Urol. 2012 Mar;187(3):845-51. doi: 10.1016/j.juro.2011.10.158. Epub 2012 Jan 15.

    PubMed 22248522

  • Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025 Jan-Feb;75(1):10-45. doi: 10.3322/caac.21871. Epub 2025 Jan 16.

    PubMed 39817679

  • Cui Y, Lu Y, Wu J, Quan C. Benefits of lymphadenectomy for upper tract urothelial carcinoma only located in the lower ureter: a bicentre retrospective cohort study. Front Oncol. 2023 Apr 14;13:1115830. doi: 10.3389/fonc.2023.1115830. eCollection 2023.

    PubMed 37124512

  • Lee HY, Chang CH, Huang CP, Yu CC, Lo CW, Chung SD, Wu WC, Chen IA, Lin JT, Jiang YH, Lee YK, Hsueh TY, Chiu AW, Chen YT, Lin CM, Tsai YC, Chen WC, Chiang BJ, Huang HC, Chen CH, Huang CY, Wu CC, Lin WY, Tseng JS, Ke HL, Yeh HC. Is Lymph Node Dissection Necessary During Radical Nephroureterectomy for Clinically Node-Negative Upper Tract Urothelial Carcinoma? A Multi-Institutional Study. Front Oncol. 2022 Apr 29;12:791620. doi: 10.3389/fonc.2022.791620. eCollection 2022.

    PubMed 35574295

Questions about this trial

What is this clinical trial studying?

A study testing Template Lymph Node Dissection and Selective Lymph Node Resection in people with Upper Tract Urothelial Carcinoma and Lymph Node Dissection, run by Tianjin Medical University Second Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 25 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Shimiao Zhu, MD, PhD (+86 88328607, zhushimiao@tmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Disease-Free Survival (DFS) (time frame: From date of randomization until the date of first documented progression, recurrence, or death from any cause, assessed up to 5 years. (Assessments: every 3 months for the first 2 years, then every 6 months for years 3-5.)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07321210, which also lists 27 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in